Raghuram Selvaraju, Head of Healthcare Equity Research at Aegis Capital, outlines reasons why Pfizer will likely to seize control of U.K rival AstraZeneca.
CNBC's Meg Tirrell reports both Pfizer and AstraZeneca CEOs are facing tough questions by the UK Parliament on the possible merger.
Pfizer's CEO Ian Read is getting grilled at a hearing in the U.K. over the company's proposed takeover of AstraZeneca, reports CNBC's Meg Tirrell.
The CEO of AstraZeneca told CNBC the U.K. pharmaceutical giant was big enough to thrive alone, but would still consider a takeover bid.
Valeant said it planned to "improve" its $47 billion takeover offer for drugmaker Allergan, a day after the U.S. company rejected the bid.
CNBC's Meg Tirrell reports the latest details on U.S. drug maker Pfizer's bid to buy AstraZeneca.
Pascal Soriot, AstraZeneca CEO, says the group has what it takes to succeed on its own and that its "stand-alone strategy" will create value for its shareholders.
AstraZeneca has the "critical mass" to succeed internationally, Pascal Soriot, CEO of AstraZeneca told CNBC, also discussing the group¿s pipeline.
CNBC's Meg Tirrell reports the latest details on U.S. drugmaker Pfizer's bid to buy AstrZeneca.
Barbara Ryan, FTI Consulting, weighs in on Pfizer's bid to acquire AstraZeneca, and what's driving consolidation in the pharma space.
Pfizer CEO Ian speaks before British lawmakers on his company's bid for AstraZeneca, reports CNBC's Meg Tirrell.
Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.
Ian Read, CEO of Pfizer, says there is a "very strong industrial rationale" behind its AstraZeneca's takeover bid, as the groups' pipelines would both benefit from being combined.
Scott Moeller, director of the M&A research centre at Cass Business School, discusses the potential AstraZeneca takeover and Pfizer's strategy.
Ranjith Gopinathan, program manager for life sciences and health care practice at Frost & Sullivan, explains why he believes the Pfizer/AstraZeneca deal would be positive.
Tony Burke, assistant general secretary of Unite, says Pfizer's promises to keep jobs in and research in the U.K. are "not worth the paper they are written on".
Katy Clark MP, a member of the U.K. parliament's business select committee, and Roger Barker, director of corporate governance at the Institute of Directors, discuss the concerns surrounding Pfizer's bid to take over AstraZeneca.
Living Proof co-owner and actress Jennifer Aniston, discusses the consumer hair care market and how current beauty companies are failing shoppers.
Allergan has rejected a $47 billion takeover bid by Valeant Pharmaceuticals. The "Squawk on the Street" news team discuss m&a in pharmaceuticals and the IPO market.
Pfizer is "back on the attack" and trying to make sure the takeover of AstraZeneca is seen as being "all about science and medicine", CNBC's Catherine Boyle reports.